OASYS
Oncogenic Addiction and Sensitivity to Immunotherapy Strategies Group
Together, let’s overcome cancer.

About OASYS
While immunotherapy has transformed oncology, overcoming resistance in “cold” solid tumors remains a critical hurdle in cancer care. The OASYS group aims to address this challenge by identifying novel therapeutic associations and optimizing standard immunotherapy combinations. Our research focuses on how targeting specific oncogenic pathways and limiting tolerogenic soluble factors can modulate the tumor microenvironment to trigger effective immune responses.
To achieve these goals, the lab employs a highly translational approach, bridging molecular mechanism studies with advanced human ex vivo models, public dataset mining, and patient tumor samples. Utilizing cutting-edge technologies like spectral cytometry and scRNAseq, we finely map tumor evolution to discover predictive biomarkers and fuel early-phase clinical trials.
Through close integration with our academic, clinical, and industrial partners, our group is deeply committed to accelerating the journey from preclinical concept validation to clinical reality, ultimately striving to develop innovative immuno-oncology strategies that improve patient outcomes.
Science
Discover our expertise from chemistry to biological evaluation for the development of your theranostic solution.

Our team
-
Emeric Limagne
Group Leader
Emeric Limagne, Ph.D. is a Researcher in Tumor Immunology at the Centre Georges-François Leclerc (CGFL). He is also a member of the INSERM UMR 1231 research unit at the Université de Bourgogne.
Originally from France, Emeric Limagne completed his Master’s studies with a focus on cellular biology and immunology.Then Emeric pursued his Ph.D. at the Université de Bourgogne. Mentored by Prof. François Ghiringhelli, Emeric’s thesis was on cancer immunology and the tumor microenvironment. In his subsequent post-doctoral and research work, Emeric has focused extensively on the interactions between cancer cells and the immune system at the CGFL.
His current research focus is on tumor immunology with a specific interest in the tumor microenvironment, immunogenic cell death, and the mechanisms of resistance to immunotherapies in cancer.
-
Anthony Di Roio
Ph.D. Researcher
Anthony is a Ph.D. researcher in the tumor immunology team at the Centre Georges-François Leclerc (CGFL) and INSERM UMR 1231.
His current research focuses on targeting the tumor immune stroma and understanding the mechanisms of resistance to cancer therapies.
Previously, Anthony completed his research at the Cancer Research Center of Lyon (CRCL), where he investigated how MDR1-expressing CD4+ T cells resist chemotherapy and their role in anti-cancer immunity.
-
Pauline Russo
3rd-year Ph.D. student
Pauline is a 3rd-year Ph.D. student at the Université de Bourgogne, conducting her research at the Centre Georges-François Leclerc (CGFL).
Her current research interests focus on optimizing the immunological and therapeutic effects of personalized vaccination by targeting oncogenic pathways in non-immunogenic tumors.
Previously, her research work has involved studying cancer cell-derived cytokines, such as IL-1β, and their role in reversing chemo-immunotherapy resistance in lung cancer.
-
Cyriane Poirier
1st-year Ph.D. student
Cyriane is a 1st-year Ph.D. student at the Université de Bourgogne, working in the INSERM UMR 1231 unit at the Centre Georges-François Leclerc (CGFL).
Her current research interests focus on the tumor microenvironment and identifying targeted therapy combinations to sensitize ‘cold’ tumors, such as triple-negative breast cancer, to immunotherapies. -
Lorenza Pillas
Research Team
Lorenza is a 1st-year student pursuing a degree at EPHE, conducting her research at the Centre Georges-François Leclerc (CGFL).
Her current research interests focus on tumor immunology and interactions within the cancer microenvironment. -
Lisa Nuttin
Research Team
Lisa is a Research Technician at the Centre Georges-François Leclerc (CGFL) and INSERM UMR 1231. Her current work supports translational research on the tumor microenvironment, specifically focusing on the cross-talk between innate immune cells like macrophages or NK cells and T-cells in ‘cold’ tumors.
-
Charlène Latour
Research Team
Lab Alumni
-
Jeanne Aubin
Medical Intern
-
Loïck Galland
Oncologist
-
Laura Kalfeist
PhD in Immuno-oncology
-
Marjorie Bon
-
Samia Kada-Mohammed
Surgeon
-
Fumet Jean-David
Oncologist
-
Amandine Vallet
PhD in Cellular Oncology
-
Courèche Kaderbhaï
Oncologist
Latest news
Selected publications
- Cancer cell-derived IL-1β reverses chemo-immunotherapy resistance in non-small cell lung cancer (2025)
- Stearoyl-CoA desaturase-1 controls the differentiation and antitumoral function of Th9 lymphocytes (2026)
- Phosphatidylcholine and CHPT1 as Central Drivers of Chemoresistance in Colorectal Cancer: Lipidomic and Functional Insights (2026)
Our partners
Our sponsors

Graduate students interested in laboratory rotations, as well as highly motivated postdoctoral candidates passionate about immunotherapy research, are invited to apply.
